26 September 2018
Scientists of Sechenov University took part in creation of cancer nanotechnology enables targeted delivery of substantial payloads of drugs to cancer sites with concomitant reduction of side effects due to the lesser accumulation in the critical organs.
This prompts loading of nanocarriers with therapeutic cargo and contrast agents, allowing combined cancer therapy and tumor visualization, respectively. The resultant hybrid complex showed high therapeutic efficiency and high imaging contrast both in vitro and in vivo.
The scientific results were published in the Proceedings of the National Academy of Sciences (PNAS).
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Four cancer centers opened in Russia in 2023
26 April 2024
Russia and the UAE can simplify the drug registration process
26 April 2024
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024